Halberd Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HALB research report →
About the company
Halberd Corporation is a biotechnology firm dedicated to pioneering therapies for neurodegenerative conditions. The company's therapeutic focus encompasses a broad range of serious illnesses, including post-traumatic stress disorder (PTSD) and chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, various forms of cancer, and disorders impacting the blood and cerebrospinal fluid. Established in 2009, Halberd Corporation operates from its headquarters in Jackson Center, Pennsylvania.
- CEO
- William A. Hartman
- IPO
- 2012
- Employees
- 3
- HQ
- Jackson Center, PA, US
Price Chart
- Market Cap
- $464.29K
- P/E
- -14.31
- P/S
- 0.00
- P/B
- -0.73
- EV/EBITDA
- -15.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 5.01%
- ROIC
- 5.56%
- Revenue
- $0 · -100.00%
- Net Income
- $-20,071 · 74.81%
- EPS
- $0.00 · 100.00%
- Op Income
- $-18,665
- FCF YoY
- 0.00%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.18
- Avg Volume
- 774.76K
Get TickerSpark's AI analysis on HALB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HALB coverage
Recent articles, reports, and earnings notes.
No research on HALB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HALB report →Similar companies
Peers in the same neighborhood.